IIQ.AU Inoviq Ltd

Healthcare Health Care Providers & Services Australian Securities Exchange
0.1350 AUD
Close of Oct 29, 2026
0.1300 0.5650
Market cap
AUD 19.0M
P/E
-
P/B
1.01x
ROE
-39.7%
Dividend yield
-
Fundamental score
1.8/5

Ratios use the latest price and the fiscal year ending Jun 2026.

Is IIQ.AU undervalued?

Graham number

The Graham number of Inoviq Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Inoviq Ltd fundamental analysis

9 of 21 checks passed

ROE 0/2

Low return on equity (-39.7%), below 10%.

ROA 0/1

Return on assets (-36.7%) is below the industry median (-0.3%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (8.8%) is above the industry median (-1.5%).

Revenue Growth 1/2

Revenue grew 2.8% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (1.5%), 40% or less.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Cash Runway 1/2

Cash covers 1.4 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 1/1

Price to book (1.0x) is below the industry median (2.0x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Inoviq Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Inoviq Ltd

INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an immunoaffinity magnetic bead-based isolation system for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium. It also offers non-invasiv…

Full company profile